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CMR and Amyloid Cardiomyopathy
Are We Getting Closer to the Biology?*Raymond Y. Kwong, MD, MPH,y Michael Jerosch-Herold, PHDz
Boston, MassachusettsIn cardiac amyloidosis, myocardial tissue histology
reveals among its salient features, the expansion of the
extracellular space, the accumulation of amyloid pro-
tein, and collagen ﬁber deposition. At the cellular level,
cytoplasmic vacuolization and decline of myoﬁbrils are
commonly seen in endomyocardial biopsies from am-
yloid patients. There is evidence that human amyloi-
dogenic light (AL) chain proteins have a cardiotoxic
effect (1), which is associated with impaired car-
diomyocyte contractile function and increased cell
death. Of similar relevance for transthyretin-related
amyloidosis (ATTR) is the fact that transthyretin
(TTR) also has a cytotoxic effect (2), causing increased
inﬂammatory and oxidative stress. How well cardiac
magnetic resonance (CMR) can identify various aspects
of pathological tissue remodeling in cardiac amyloidosis
remains a question of intense research interest.See pages 133, 143, and 157Over the last decade, CMR has identiﬁed a series
of promising image-based markers tied to car-
diomyopathic changes in amyloidosis. Initial work
has focused on imaging late gadolinium enhance-
ment (LGE), which has proven challenging in a
substantial portion of patients with suspected cardiac
amyloidosis because contrast enhancement tends to
be diffuse. This has prompted the increasing interest
in using T1 mapping in cardiac amyloidosis, which is
a method that provides a continuous measure, rather
than a “binary” contrast, as sought in LGE.*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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Radiology, Brigham and Women’s Hospital, Boston, Massachusetts. The
authors have reported that they have no relationships relevant to the
contents of this paper to disclose.In this issue of iJACC, 3 separate reports tackled
the challenging tasks of CMR of suspected cardiac
amyloidosis. Dungu et al. (3) describe a larger LGE
burden in ATTR patients than in AL patients and
extended this clinical suspicion by studying a multi-
center cohort of 100 patients who reached a ﬁnal
diagnosis of cardiac amyloidosis (50% by cardiac
histology and 50% by international guidelines). The
investigators derived a QALE (Query Amyloid Late
Enhancement) score and reported a sensitivity of
87% and a speciﬁcity of 96% in differentiating ATTR
(n¼ 51) from non–TTR-related cardiac amyloidosis
(AL: n ¼ 46; others: n ¼ 3). The derivation of
this score by Dungu et al. (3), though based on
“real-world data,” was inﬂuenced by less-than-
standardized LGE imaging protocol across 46 cen-
ters, variable scanner ﬁeld strengths, and variable
clinical use of endomyocardial biopsy. Sizing of LGE
extent is well known to be challenging in imaging of
diffusely inﬁltrated myocardium, and thus the results,
albeit intriguing, cannot obviate the role of endo-
myocardial biopsy in patients with remaining un-
certainty of their clinical diagnoses. Nonetheless, the
QALE score developed in this pilot experience would
have valuable diagnostic and prognostic implications
if the results hold up in a prospective clinical trial.
White et al. (4) propose the use of a rapid, post-
contrast, T1-based visual comparison between the
myocardium and blood pool, using an inversion-
prepared technique, which is already being used in
many centers to determine the optimal inversion time
(TI) for conventional LGE imaging, and routinely
referred to as “TI scout.” The criterion for the pres-
ence of diffuse left ventricular hyperenhancement was
that the inversion recovery was more rapid in >50%
of the myocardium compared with inversion recovery
of blood, the reverse of what is typically seen in pa-
tients without inﬁltrative cardiomyopathies. More
importantly, this study represents the largest current
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167evidence in using CMR in characterizing the prog-
nosis of suspected cardiac amyloid patients at a me-
dian follow-up of 29 months. The investigators
found a robust association of diffuse LGE with all-
cause mortality, not only in the main cohort but
also in subgroup analyses. However, whereas this
visual evaluation represents a practical and rapid way
to assess the cardiac amyloid burden, its reliability
may be inﬂuenced by variability introduced by the
severity of the systemic disease burden (which affects
availability of gadolinium in the blood-pool, and thus
blood T1), and possibly also by patient body weight,
time after contrast injection, and renal function.
Furthermore, only a minority of the cohort in this
study reached a histological diagnosis of cardiac
amyloidosis. With the speciﬁcity of shortened T1
visualization only in amoderate range, further studies
will need to address whether this visual method de-
livers enough accuracy for tracking of disease severity
and guiding any management decisions including
eliminating the need for biopsy or initiation of novel
medical therapy.
Fontana et al. (5) report high diagnostic accuracy
for detecting ATTR or AL using native (pre-
contrast) T1 mapping against patients with hyper-
trophic cardiomyopathy as control cases. This work
builds on previous observations that the native (i.e.,
pre-contrast) myocardial T1 is abnormally high in
cardiac amyloidosis, and speciﬁcally probes differ-
ences in native T1 between ATTR and AL (6,7).
The investigators propose that native T1 mapping
reﬂects on a subclinical inﬂammatory process, and it
can detect abnormal myocardial inﬁltration more
sensitively than LGE imaging in morphologically
normal gene mutation carriers. The role of native
T1 mapping, relative to mapping of extracellular
volume (8–10) remains to be more fully deﬁned.
All 3 studies provide new knowledge that may
advance our understanding of how CMR can assist
in the management of patients with suspected car-
diac amyloidosis, although all of them suffer from
the inherent bias of a cohort-control design, variable
criteria for establishment of the diagnosis of cardiac
amyloidosis, or small study size, reﬂecting the chal-
lenge of studying patients surrounding this clinical
condition. These and other CMR studies are in part
driven by the expectation that CMR can provide of
some form of noninvasive biopsy in cardiac
amyloidosis and other cardiomyopathies (11). This
presupposes that one can achieve a good under-
standing of the pathophysiological basis of changes
in relaxographic properties of myocardial tissue.
Inﬂammatory stress resulting from amyloid pro-
tein deposition is a plausible cause for prolongingthe native T1 (and T2) in the myocardium. The
native, myocardial T1 of patients with systemic
inﬂammatory diseases, such as lupus erythemato-
sus, an inﬂammatory autoimmune disease, is longer
than in healthy control subjects (12) by an amount
of similar magnitude as in the present study
Fontana et al. (5). The mechanism through which
inﬂammatory stress would increase the native
myocardial T1 is likely linked to an increase of free
water content (edema), but inﬂammation is also
associated with higher contrast enhancement,
which may be inﬂuenced by factors other than free
water content.
Some inconsistencies exist between the ﬁndings
of the current reports, morphologic features, and
natural histories of amyloid subtypes. Patients with
TTR-type amyloidosis show signiﬁcantly more
pronounced ventricular hypertrophy than do pa-
tients with systemic, immunoglobulin light-chain–
type amyloidosis. Consistent with this previous
knowledge, Dungu et al. (3) report that late-
gadolinium enhancement was pervasive in ATTR
patients and less frequent in AL patients, seemingly
suggesting that if one judges the disease pathology
by LGE, ATTR would appear to have more severe
repercussions on the left ventricle than AL would,
yet median survival time from diagnosis has been
known to be longer for ATTR patients than for AL
patients. The exacerbated hypertrophy in ATTR
raised the expectation that native T1 changes would
be elevated relative to normal myocardium and with
T1 longer in ATTR than in AL. Somewhat sur-
prising, therefore, is the ﬁnding of Fontana et al. (5)
that the native T1 was not as elevated in ATTR as it
was in AL.
The fact that the ﬁndings discussed here do not
coalesce to an entirely coherent understanding of
the different CMR parameters suggests that future
studies should be more comprehensive and should
integrate native T1, extracellular volume, T2, and
LGE. In histology, one uses various stains to
characterize tissue pathology, and the same can be
said for CMR, where relaxation properties take on
the role of virtual stains in parametric maps.
Determining the best types and methods of
“staining” myocardial tissue with CMR remains
an important challenge and opportunity, as evi-
denced by the 3 referenced papers in this issue of
iJACC.
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